Werewolf Therapeutics to Merge With Ambros in $150M All-Stock Deal
Werewolf Therapeutics and Ambros Therapeutics announce a merger and oversubscribed $150M private placement to advance a chronic pain treatment.
Werewolf Therapeutics (Nasdaq: HOWL) and privately held Ambros Therapeutics announced Thursday an all-stock merger agreement alongside a concurrent, oversubscribed $150 million private placement, signaling strong investor confidence in the newly combined entity's pain-treatment pipeline.
Once the deal closes, the combined company will carry the Ambros Therapeutics name and relocate its headquarters to San Diego, California. It is expected to trade on Nasdaq under the ticker symbol "AMBX," marking a rebrand away from Werewolf's current HOWL listing.
Read more Nike, Starbucks and GM Lose Ground to Chinese Rivals →
The strategic pivot centers on Ambros Therapeutics' neridronate development program targeting Complex Regional Pain Syndrome Type 1 — a debilitating chronic pain condition historically known as Reflex Sympathetic Dystrophy. The merger gives the program the capital structure and public-market access needed to advance through clinical development.
The fact that the $150 million private placement was oversubscribed points to robust institutional appetite for neridronate's prospects in a rare-pain indication that has long lacked approved therapies. The all-stock structure preserves cash while aligning both companies' shareholders around a single clinical thesis.
Continue reading at GlobalNewswire.
